Gilead Sciences’ HCV drugs
Gilead Sciences’ (GILD) antiviral portfolio also includes drugs to treat HCV (Hepatitis C virus) infections. The portfolio includes products like Harvoni, Epclusa, Sovaldi, and Vosevi.
The above chart compares the revenues for HCV products since 1Q16. The total revenues for HCV drugs were $1.5 billion during 4Q17—a 54.0% decline compared to $3.3 billion during 4Q16.
Harvoni is approved to treat patients with chronic HCV infections—Genotype-1, Genotype-4, Genotype-5, and Genotype-6. Harvoni reported revenues of $644 million during 4Q17—a 60.7% decline compared to $1.6 billion during 4Q16. The decline was driven by Harvoni’s lower sales across all of the markets worldwide.
Sovaldi is approved to use in combination with other drugs to treat patients with chronic HCV infections—Genotype-1 to Genotype-4. Sovaldi reported revenues of $117 million during 4Q17—a 78.4% decline compared to revenues of $541 million during 4Q16. The decline was driven by Sovaldi’s lower sales across all of the markets worldwide.
Epclusa is used to treat chronic HCV infections of Genotype-1 to Genotype-6 in patients with or without Cirrhosis. Epclusa reported revenues of $565 million during 4Q17—compared to revenues of $1.05 billion in 4Q16. The decline was driven by lower sales in US markets. The lower revenues were partially offset by strong sales in European and international markets.
Vosevi is the latest drug from Gilead Sciences’ HCV portfolio. Vosevi is approved to treat patients with chronic HCV infections of Genotype-1 to Genotype-6 in patients with or without Cirrhosis who have been previously treated with an NS5A inhibitor. Vosevi reported revenues of $170 million during 4Q17. US sales were $150 million during 4Q17.